With 1.32 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $35.06 whereas the lowest price it dropped to was $32.92. The 52-week range on MTSR shows that it touched its highest point at $47.40 and its lowest point at $12.30 during that stretch. It currently has a 1-year price target of $57.33.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MTSR was down-trending over the past week, with a drop of -10.28%, but this was up by 17.47% over a month. Three-month performance surged to 39.07% while six-month performance rose 19.96%. For the next quarter, that number is -0.76. This implies an EPS growth rate of 77.36% for this year and -9.15% for next year.
Float and Shares Shorts:
At present, 104.89 million MTSR shares are outstanding with a float of 50.72 million shares on hand for trading. On 2025-07-15, short shares totaled 9.93 million, which was 947.0000000000001 higher than short shares on 1749772800. In addition to Dr. Clive A. Meanwell M.D., Ph.D. as the firm’s Co-Founder & Executive Chairman, Mr. Christopher Whitten Bernard serves as its Co-Founder, President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.78014 of MTSR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, MTSR reported revenue of $0.0 and operating income of -$71993000.0. The EBITDA in the recently reported quarter was -$66581000.0 and diluted EPS was -$0.66.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MTSR analysts setting a high price target of 65.0 and a low target of 45.0, the average target price over the next 12 months is 57.33333. Based on these targets, MTSR could surge 94.9% to reach the target high and rise by 34.93% to reach the target low. Reaching the average price target will result in a growth of 71.91% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$4.07667 being high and -$4.07667 being low. For MTSR, this leads to a yearly average estimate of -$4.07667.
